Sequence information
Variant position: 26 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 805 The length of the canonical sequence.
Location on the sequence:
WLLLSLVAVTAAQSTIEEQA
K TFLDKFNHEAEDLFYQSSLA
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human WLLLSLVAVTAAQSTIEEQAK TFLDKFNHEAEDLFYQSSLA
Mouse WLLLSLVAVTTAQSLTEENAK TFLNNFNQEAEDLSYQSSLA
Rat WLLLSLVAVATAQSLIEEKAE SFLNKFNQEAEDLSYQSSLA
Bovine WLLLSLVAVTAAQSTTEEQAK TFLEKFNHEAEDLSYQSSLA
Cat WLLLSFAALTAAQSTTEELAK TFLEKFNHEAEELSYQSSLA
Baker's yeast WYI---NPSGFAKDTQDEEYV QHHDNVNPTIP---------
Fission yeast ------MSLSYLSSSSQKSFE SFRQEESPACN---------
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
Chain
18 – 805
Angiotensin-converting enzyme 2
Chain
18 – 708
Processed angiotensin-converting enzyme 2
Topological domain
18 – 740
Extracellular
Alternative sequence
1 – 356
MSSSSWLLLSLVAVTAAQSTIEEQAKTFLDKFNHEAEDLFYQSSLASWNYNTNITEENVQNMNNAGDKWSAFLKEQSTLAQMYPLQEIQNLTVKLQLQALQQNGSSVLSEDKSKRLNTILNTMSTIYSTGKVCNPDNPQECLLLEPGLNEIMANSLDYNERLWAWESWRSEVGKQLRPLYEEYVVLKNEMARANHYEDYGDYWRGDYEVNGVDGYDYSRGQLIEDVEHTFEEIKPLYEHLHAYVRAKLMNAYPSYISPIGCLPAHLLGDMWGRFWTNLYSLTVPFGQKPNIDVTDAMVDQAWDAQRIFKEAEKFFVSVGLPNMTQGFWENSMLTDPGNVQKAVCHPTAWDLGKGDF -> MREAGWDKGG. In isoform 2.
Mutagenesis
19 – 19
S -> P. Increases slightly the interaction with RBD domain of SARS-CoV-2 spike protein.
Mutagenesis
24 – 26
QAK -> KAE. Slightly inhibits interaction with SARS-CoV spike glycoprotein.
Mutagenesis
24 – 24
Q -> T. Increases slightly the interaction with RBD domain of SARS-CoV-2 spike protein.
Mutagenesis
25 – 25
A -> V. Increases slightly the interaction with RBD domain of SARS-CoV-2 spike protein.
Mutagenesis
27 – 27
T -> Y. Increases slightly the interaction with RBD domain of SARS-CoV-2 spike protein. In sACE2.v2.2; increases interaction with RBD domain of SARS-CoV-2 spike protein; when associated with Y-330 and L-386.
Mutagenesis
29 – 29
L -> F. Increases slightly the interaction with RBD domain of SARS-CoV-2 spike protein.
Mutagenesis
31 – 31
K -> D. Abolishes interaction with SARS-CoV spike glycoprotein.
Mutagenesis
31 – 31
K -> Y. Increases slightly the interaction with RBD domain of SARS-CoV-2 spike protein.
Mutagenesis
33 – 33
N -> D. Increases slightly the interaction with RBD domain of SARS-CoV-2 spike protein.
Mutagenesis
34 – 34
H -> A. Increases slightly the interaction with RBD domain of SARS-CoV-2 spike protein.
Mutagenesis
37 – 37
E -> A. No effect on interaction with SARS-CoV spike glycoprotein.
Mutagenesis
38 – 38
D -> A. No effect on interaction with SARS-CoV spike glycoprotein.
Mutagenesis
39 – 39
L -> R. Increases slightly the interaction with RBD domain of SARS-CoV-2 spike protein.
Mutagenesis
40 – 40
F -> D. Increases slightly the interaction with RBD domain of SARS-CoV-2 spike protein.
Mutagenesis
41 – 41
Y -> A. Strongly inhibits interaction with SARS-CoV spike glycoprotein.
Mutagenesis
41 – 41
Y -> R. Increases slightly the interaction with RBD domain of SARS-CoV-2 spike protein.
Mutagenesis
42 – 42
Q -> L. Increases slightly the interaction with RBD domain of SARS-CoV-2 spike protein.
Helix
23 – 52
Literature citations
Submission
SeattleSNPs variation discovery resource;
Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA]; VARIANT ARG-26;
Genetic variability of human angiotensin-converting enzyme 2 (hACE2) among various ethnic populations.
Li Q.; Cao Z.; Rahman P.;
Mol. Genet. Genomic Med. 0:0-0(2020)
Cited for: VARIANTS ARG-26; VAL-468; SER-638 AND ASP-720;
Disclaimer:
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.